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1. Introduction  
The neuromuscular disorders are a heterogeneous group of genetic diseases characterized 
by progressive degeneration and impaired regeneration of skeletal muscle, resulting in 
weakness. The mobility of patients is very reduced, leading, depending on the disease 
severity, to wheelchair dependency and reduced life expectancy and quality. 
Currently there are no proven treatments for these diseases, except for palliative measures 
to improve a patient’s quality of life. Nevertheless, cell therapy using embryonic or somatic 
stem cells is considered to offer the best potential for success, and many projects are now 
being undertaken to evaluate the therapeutic possibilities of this approach. 
Theoretically, due to their pluripotency, embryonic stem cells can give rise to any type of 
tissue, and raises the possibility of successfully treating many diseases. However, a simple 
injection of ES cells into various body locations in model organisms often leads to formation 
of undesirable teratomas and not to healthy new tissues. Accordingly, ES cells must be 
partially differentiated and selected prior to injection to increase the likelihood of 
implantation and growth of tissue exhibiting differentiation of the desired type. 
Although some modest advances have been achieved, to date the use of ES cells for therapy 
of neuromuscular disorders still remains a distant goal. In this review we mainly consider 
the role of embryonic stem cells in neuromuscular therapeutic approaches.  
2. Muscular dystrophies  
The neuromuscular disorders form a heterogeneous group of genetic diseases characterized 
by progressive loss of muscular strength caused by defects in or absence of muscle proteins 
and also to imbalance between rates of tissue degeneration and regeneration. There is great 
clinical variability, ranging from extremely mild to severe forms (Emery, 2002). 
More than 30 genetically defined forms are recognized, and in the last decade, mutations in 
several genes coding for the sarcolemmal, sarcomeric, cytosolic or nuclear muscle proteins 
have been reported. Deficiencies or loss of function of these proteins leads to variable 
degrees of progressive muscle degeneration, which in turn results in progressive loss of 
motor ability (Vainzof et al., 2003). The principle proteins involved occupy specific niches in 
muscle cells: dystrophin (Dmd), sarcoglycan (Sgca) and dysferlin (Dysf) are sarcolemmal or 
peri-sarcolemmal proteins; laminin alpha 2 (Lama2) and collagen type VI (Col6) are 
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extracellular matrix proteins; telethonin (Tcap) and actin alpha 1 (Acta1) are sarcomeric 
proteins; calpain 3 (Capn3) and FKRP (Fkrp) are cytosolic enzymes; and emerin (Emd) and 
lamin A/C (Lmna/c)are nuclear proteins (Figure 1). 
 
 
Fig. 1. Schematic representation of proteins involved in the process of muscle degeneration 
in neuromuscular disorders, localized at the sarcolemma, the sarcomere, the cytosol and the 
nucleus. The boxes contain the disease name associated with the protein. LGMD – limb-
girdle muscular dystrophy; EDMD- Emery-Dreifuss muscular dystrophy; FKRP – fukutin-
related protein; NOS – nitric oxide synthase. 
Defects in components of the dystrophin-glycoprotein complex (DGC) are known to be an 
important cause of different forms of muscular dystrophies (Ervasti & Campbell, 1993; 
Yoshida & Ozawa, 1990). The DGC is an oligomeric complex connecting the 
subsarcolemmal cytoskeleton to the extracellular matrix.  The DGC consists of dystroglycan 
(- and -DG), sarcoglycan (, -, -, - and -SG) and syntrophin/dystrobrevin sub-
complexes. The intracellular link of the DGC is the protein dystrophin that plays an 
important structural role in muscle fibers.  Mutations in the dystrophin gene cause the most 
common form of neuromuscular disorder, namely X-linked Duchenne muscular dystrophy 
(DMD) (Hoffman et al., 1987) with a frequency of 1 in 3000 males in most populations 
studied. Further, this disease epitomises the severe need for efficient treatment modalities, 
since 1/3rd of all patients arise from new mutations and the disease frequency can never be 
modulated efficiently by genetic counselling approaches. 
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Mutations in the genes coding the four SG proteins cause severe forms of limb-girdle 
muscular dystrophies type LGMD2D, 2E, 2C and 2F. The peripheral membrane glycoprotein 
-DG, a receptor for the heterotrimeric basement membrane protein laminin-2, binds to -
DG and so completes the connection from the inside to the outside of the cell (Straub and 
Campbell, 1997). Mutations in the Lama2 gene, encoding the 2 chain of laminin-2, cause 2-
laminin deficiency, and a severe form of congenital muscular dystrophy (CMD1A) linked to 
human chromosome 6q (Tomé et al., 1994). In addition, some forms of muscular dystrophy 
have recently been associated with genes encoding putative or known glycosyltransferases. 
Muscle protein analysis in these patients shows a hypoglycosilation of -dystroglycan and a 
consequent reduction of numerous ligands components of the extracellular matrix, such as 
laminin 2 (Muntoni et al., 2004).  Other milder forms of muscular dystrophy are caused by 
mutations in genes coding the enzyme calpain 3 (Capn3), the sarcolemmal protein dysferlin 
(Dysf), and the sarcomeric protein telethonin (Tcap) (Vainzof & Zatz, 2003). 
2.1 Animal models for neuromuscular diseases 
Several animal models, manifesting phenotypes observed in neuromuscular diseases have 
been identified in nature or generated in laboratory. These models generally present 
physiological alterations observed in human patients, and can be used as important tools for 
genetic, clinical and histopathological studies (Vainzof et al., 2008). 
The mdx mouse is the most widely used animal model for Duchenne muscular dystrophy 
(DMD) (Bulfield et al., 1984). Although it is a good genetic and biochemical model, 
presenting total deficiency of dystrophin in muscle, this mouse is not useful for clinical 
comparisons, because of its very mild phenotype. The canine golden retriever MD model 
presents a more clinically relevant model for DMD in humans due to the much larger size of 
the animals, significant muscle weakness progression and premature lethality.   
Models for autosomal recessive limb-girdle MD include the SJL/J mice that develop 
spontaneous myopathy resulting from a mutation in the Dysferlin gene, which is a 
specific model for LGMD2B (Bittner et al., 1999). For the human sarcoglycanopathies (SG), 
the BIO14.6 hamster is the spontaneous animal model for -SG deficiency, while some 
canine models with deficiency of SG proteins have also been identified (Straub et al., 
1998). More recently, using homologous recombination in embryonic stem cells, several 
mouse models have been developed with null mutations in each one of the four SG genes.  
All sarcoglycan-null animals display a progressive muscular dystrophy of variable 
severity, and share the property of a significant secondary reduction in the expression of 
the other members of the sarcoglycan subcomplex, and other components of the 
Dystrophin-glycoprotein complex.   
Mouse models for congenital MD include the dy/dy (dystrophia-muscularis) mouse, and the 
allelic mutant dy2J/dy2J mouse, both presenting a significant reduction of 2-laminin in the 
muscle and a severe phenotype. The myodystrophy mouse (Largemyd), harbors a mutation 
in the glycosyltransferase Large, which leads to altered glycosylation of -DG, and a severe 
phenotype (Grewal et al., 2001). 
Other informative models for muscle proteins include the knockout mouse for myostatin, 
demonstrating that this protein is a negative regulator of muscle growth (Patel & Amthor, 
2005).  Additionally, the stress syndrome in pigs, caused by mutations in the porcine Ryr1 
gene, helped to localize the gene causing malignant hyperthermia and Central Core 
myopathy in humans (Yang et al., 2006). 
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The study of animal models for genetic neuromuscular diseases, in spite of some differences 
with their equivalent human disease phenotypes, can provide important clues to 
understanding the pathogenesis of these disorders in humans and are also very valuable for 
testing strategies for cellular therapeutic approaches. 
3. Muscle development 
Activating key genes in a sequence similar to that occurring in the normal organism is a 
reasonable approach to obtain differentiated muscle cells in vitro. This depends on 
understanding the gene pathways leading to myogenic differentiation.  
Skeletal muscle development can be divided into a number of principal stages: 
determination of the cell fate (myoblast formation); myoblasts proliferation; alignment and 
fusion of myoblasts; formation of myotubes; maturation of myotubes and muscle fibre 
formation (Figure 2). Different molecular factors regulate each step in a particular and very 
ordered manner. 
 
 
Fig. 2. Schematic of the myogenic cascade 
3.1 Anatomy of embryonic myogenesis – Myotome formation 
The majority of skeletal myogenic progenitors arise from somites, which are transitory 
condensations of paraxial mesoderm on either side of the neural tube and notochord. As the 
maturation of somites progresses, myogenic progenitor cells are confined to the epithelium 
of the dermomyotome, which give rise to the dermis and the skeletal muscle of the trunk 
and limbs (Buckingham, 2006). 
The dermomyotome is subdivided into the hypaxial dermomyotome – the source of the 
lateral trunk muscles and limb muscles – and the epaxial dermomyotome – the source of the 
deep back musculature (Parker et al., 2003). In this structure, it is possible to distinguish two 
lips: the hypaxial and epaxial lips, from which cells delaminate and migrate under the 
dermomyotome, forming the myotome, an intermediate structure (Buckingham, 2001) 
(Figure 3). 
3.2 Molecular markers and regulatory factors 
Pax3 and Pax7 are markers for cells derived from the dermomyotome and recently formed 
muscle masses. Pax3 expression is involved in progenitor muscle cell formation and is 
essential for the definition and migration of these cells to their proper location in the 
body. Pax3 acts mainly during embryogenesis, while Pax7 is more important in adult 
myogenesis. 
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Fig. 3. The origin of different muscles in the embryo. VLL – ventral lateral lip. DML – dorsal 
medial lip. (Adapted from Buckingham, 2001).  
The induction of myogenesis in the cells of somites is conducted by factors secreted by the 
notochord and neural tube: various members of the Wnt family and Shh, are responsible for 
the activation of MRFs (myogenic regulatory factors). Expression of Ctnnb1 (┚-catenin) 
dependent Wnt6 signalling is important for the maintenance of the epithelial structure of the 
dermomyotome that is essential for the ordered progression of myogenesis. In epaxial 
muscle, Wnt family members are involved in Myf5 and MyoD regulation through a complex 
cascade of gene regulation that includes the action of Shh as a positive regulator of Myf5 
(Parker et al., 2003) (Figure 4 A). 
The MRFs concerned are MyoD, Myf5, myogenin and Myf6 (Mrf4) and each one has a 
defined role in regulating skeletal muscle development and differentiation, directing the 
expression of genes responsible for the formation of the contractile machinery of the muscle 
(Bryson-Richardson & Currie, 2008). All have a homologous bHLH domain, required for 
DNA binding and dimerization with transcription factors of the E-protein family. The 
complexes of MRF-E proteins bind to a specific consensus sequence found in the promoters 
of many muscle-specific genes.  
In hypaxial muscle, the MRFs are up-regulated by Pax3, which in turn, is regulated by 
family members of the sine oculis homeobox (Six) and eyes absent (Eya) genes (Bryson-
Richardson & Currie, 2008) (Figure 4 B). 
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Fig. 4. Gene regulatory networks in A- epaxial muscle (left) and in B- hypaxial muscle 
(right). 
Another important family of transcription factors is the myocyte enhancer factor-2 (Mef2), 
also involved in the expression of many muscle-protein genes in mouse (Naya & Olson, 
1999). The Mef2 family acts in conjunction with MRFs, especially Myf6 and Myog 
(myogenin), to coordinate myoblast terminal differentiation.  
3.3 Myogenesis in the adult – muscle regeneration 
The cells responsible for regeneration in adult muscle are the satellite cells, localized under 
the basal lamina of muscle fibers. The satellite cells are partially undifferentiated myogenic 
precursor cells capable of both self-renew and differentiation into new myogenic cells 
(Relaix & Marcelle, 2009). 
In response to injury, and under the stimulus of several myogenic factors, these cells are 
activated, start to proliferate and differentiate, fuse to pre-existing fibers (hypertrophy), or 
generate new fibers (hyperplasia) in a process recapitulating muscle development (Hawke 
& Garry, 2001). Myogenic determinants involve the components of the family of 
transcription factors called muscle regulatory factors (MRFs), include:  a) Myf5 and Myod1, 
responsible for muscle-cell type determination and satellite-cells activation; b) Myf6 (also 
called Mrf4) and Myog, responsible for muscle differentiation (Brand-Saberi & Christ, 1999). 
In addition to satellite cells, there are other cell types that contribute to muscle regeneration: 
bone-marrow derived cells (Ferrari et al., 1998), muscle side-population cells (Gussoni et al., 
1999), CD34+/Sca1+ cells (Torrente et al., 2001; Lee et al., 2000) and cells of vascular origin 
(Figure 5). 
The regenerative capacity of the satellite cells, however, is finite, and the exhaustion of the 
pool of precursor cells is an important factor contributing to the progressive muscle 
deterioration observed in human and murine muscular dystrophy. In fact, the exhaustion of 
satellite cells is the primary cause of onset of symptoms in Duchenne muscular dystrophy.  
A B
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Fig. 5. Adult myogenesis and precursors cell types. Adapted from Parker et al., 2003. 
Thus, cell therapies for muscular dystrophies can also focus on the re-establishment of the 
muscle’s satellite cell pool, which reduces rapidly when there are excessive cycles of 
degeneration and regeneration.  
4. ES cells in myogenic differentiation 
Any attempt to direct the differentiation of ES cells must be designed so that the majority of 
cells will start to differentiate, as far as possibly, simultaneously into the desired cell type 
with avoidance of teratoma formation caused by non-committed pluripotent stem cells. 
Induction of appropriate myogenesis is a relatively difficult task given the unique 
architecture of muscle tissue. 
There are three main potential approaches to directed differentiation of ES cells into muscle: 
the use of muscle specific growth and differentiation factors, genetic modifications and use 
of genetically modified feeder cells (Grivennikov, 2008). The first two have already been 
tested for myogenic induction, but to date, there are no reports on the use of modified 
feeder cells for this purpose. 
For the differentiation of ES cells into different cell lineages, the cells must be cultivated in 
aggregates called embryoid bodies (EBs) by the hanging drop method (Figure 6), in which 
the 3-dimensional structure of the embryoid bodies, in combination with application of 
growth factors favouring myogenesis, encourages the stem cells to differentiate into 
myoblasts. The ES cells are first cultivated in drops of medium containing an exact number 
of cells leading to formation of EBs within 2 days, following which, the EBs are transferred 
into suspension cultures for some additional days resulting in adhesion of the EBs onto the 
bottom of tissue culture plates. The medium for EB cultivation is changed for one 
supporting myogenic differentiation at the time of EB adhesion. Studies suggest that the EBs 
need to be cultivated for five days in the suspension phase to obtain maximal differentiation 
into skeletal muscle cells. 
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Fig. 6. Hanging drop method 
4.1 In vitro induction of myogenesis 
The use of chemical compounds to induce differentiation is a quite simple approach based 
on media supplementation. In some cases, different cell types can be obtained from the same 
compound according to the substance’s concentration. For instance, 1µM retinoic acid 
causes neuronal differentiation, while 25nM retinoic acid enhances skeletal myogenesis 
(Kennedy et al., 2009). 
One of the first reports of myogenic differentiation of ES cells was reported by Rohwedel et al. 
(1994), based on protocols developed by Wobus et al. in 1988 (2002), which depend on a prior 
differentiation in embryoid bodies followed by a posterior treatment with 1% DMSO 
(dimethyldisulfoxide) or 10-8M retinoic acid. The myogenic cells obtained in this work were 
identified as myoblasts and myotubes by hematoxylin-eosin staining. The first myosin-positive 
and desmin-positive skeletal muscle cells appeared four days after EB adhesion. Myogenin-
positive myocytes were identified after six days and fusion into myotubes on the seventh day. 
Neuronal cells also appeared mostly before the differentiation of skeletal muscle cells, which 
reached a maximum in nine days. However, some EB outgrowths containing ES cells, which 
decreased with prolonged time of differentiation. Using RT-PCR the authors detected 
expression of the myogenic regulatory factors myogenin, Myf5, Myf6 and Myod1, indicating 
that ES myogenic differentiation in vitro resembles myogenesis in vivo (Rohwedel et al., 1994).  
Retinoic acid (RA) is a derivate of vitamin A and has different roles in various processes in 
embryonic development and regulates the expression of several hundreds of genes 
(Blomhoff & Blomhoff, 2006), including MRFs. In stem cells and myoblast cells lines, RA 
enhances skeletal myogenesis at low concentrations (Edwards & McBurney, 1983; Halevy & 
Lerman, 1993; Albagli-Curiel et al., 1993, as cited in Kennedy et al., 2009). In the work of 
Kennedy et al. (2009), mouse ES cells and P19 cells (pluripotent embryonal carcinoma cells) 
were differentiated with various RA concentrations, ranging from zero to 50 nM and 
1%DMSO, that promotes skeletal myogenesis, but not cardiogenesis. They detected 
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increasing transcript levels of Meox1, Pax3 and Myod1 (all skeletal muscle markers) in the 
presence of various concentrations of RA by RT-PCR and showed that transcription peaked 
at a concentration of 25nM. 
Prelle et al. (2000) overexpressed the Igf2 gene (insulin-like growth factor 2) in mouse 
embryonic stem cells to evaluate this protein as a stimulator of myogenesis. Igf2 was 
identified as an autocrine differentiation factor in myoblasts (Stewart et al., 1996, as cited in 
Prelle et al., 2000). It is also a survival factor during the transition from proliferation to 
differentiation in myoblasts and overexpression of Igf2 in myoblasts results in enhanced 
differentiation characterized by accelerated expression of myogenin mRNA and extensive 
myotube formation (Stewart & Rotwein, 1996, as cited in Prelle et al., 2000). Embryoid 
bodies were formed by overexpression of Igf2 in ES cells and myocytes were observed three 
days after adhesion, with myotube formation four days later and commencement of 
myotube contraction after ten days. They also detected the expression of the myogenic 
proteins titin and sarcomeric Myhc (myosin heavy chain). On the last day of differentiation 
(day 23), the large contracting myotubes showed a regular sarcomeric organization of both 
titin and myosin proteins. 
By semi-quantitative RT-PCR, the expression onset and intensity of the skeletal muscle-
specific genes Myf5, Myod1 and Myog showed an increase in EB outgrowths overexpressing 
Igf2, with a similar pattern of expression to that occurring in vivo. Compared with non-
transformed cells, the cells overexpressing Igf2 showed an accelerated myogenic 
differentiation, associated with enhanced expression of MRFs, without effects in the 
sarcomeric structural organization. 
We recently tested different factors for differentiating murine embryonic stem cells into 
muscle. In terms of morphology, the cells obtained are very similar to myoblasts in primary 
culture. The cells obtained also express mRNA from some proteins typical of the process of 
myogenesis, but proteins of mature muscle were not detected. To induce myogenesis in 
mES cells, EBs were cultured in media with 1%DMSO or 5µL of 10-7M Igf2. After 13 days, 
cells were harvested for mRNA and protein analysis. Cells treated with Igf2 visually seemed 
to differentiate more rapidly and with a larger proportion of cells morphologically similar to 
myoblasts than the cells treated with DMSO (data not published) (Figure 7).  
 
 
Fig. 7. Embryoid body from mES cells treated with Igf2 twelve days after adhesion. Cells 
indicated by the arrows are similar in morphology to myoblasts. 
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4.2 In vivo experiments and potential of therapies for NMD  
Due to the lack of any available therapy for NMDs, cell therapy has been suggested as a 
promising alternative.  Several attempts to use adult stem cells have been carried out, but 
with limited results.  However, due to their greater pluripotency, ES cells show a greater 
potential for cell therapy, but can also form teratomas, when simply injected into the 
organism without predifferentiation, which must be avoided. Methods must be 
developed for inducing differentiation of the ES cells into the desired cell type before 
therapy, in such a way as to obtain a uniform population of differentiated cells, and, ideally, 
without the presence of undifferentiated ES cells.  
Although there are a reasonable number of articles describing derivation of cell lines with 
some skeletal muscle features, the functional results are far from ideal and more basic 
research into in vitro culturing procedures is required. The skeletal muscle tissue has a 
unique architecture, and it is very complicated to reproduce this in vitro, rendering it 
impossible to obtain totally differentiated cells prior to transplantation. Accordingly, 
transplants are best made with cells that are already committed to differentiating into the 
myogenic lineage but have not yet completed the process, which will occur in vivo following 
transplantation.  
Co-culturing of muscle stem/precursor cells from skeletal muscle with EB outgrowths can 
induce myogenic differentiation in vivo. This was achieved by Bhagavati & Xu, (2005) by 
obtaining muscle from normal mice and deriving ES cells by pre-plating muscle fragments 
and culturing EBs over them. The myogenic differentiation obtained in this manner is 
probably due to the myogenic stem/precursor cells being provided an optimal 
developmental environment by inductive signals for the EBs. Alternatively, it is possible 
that the occasional cell fusion between ES cells and myogenic precursor cells, results in the 
reprogramming of a limited number of ES cells. To test the potential of these cells to form 
skeletal muscle in vivo, the ES cells derived from co-culturing were injected into mdx mice 
via intramuscular injection. The muscles were analyzed after two weeks by 
immunohistochemical and in situ hybridization analyses. Dystrophin positive fibers that 
were lying on the surface of recipient muscle fibres were observed in 2 out of 8 injected 
mice. However, no functional evaluation was performed to test whether this newly derived 
muscle tissue was functionally normal (Bhagavati & Xu, 2005). 
Zheng et al. (2006) used three different media, and treatment with 10mM 5-azacytidine in 
some experiments, to induce myogenic differentiation in EBs derived from hES cells. The 5-
azacytidine treatment reduced cell proliferation and caused the cells to elongate. The 
expression analysis showed that the drug decreased the expression of Met and Pax3, but 
increased the expression of Pax7 and Myod1. The expression of Myf5, Des (desmin), Myhc, 
Tnni1 (troponin I), Ncam1 was observed under all culture conditions, but occurred in the 
absence of myotube and myofiber formation. This indicates that, although the treated cells 
had the potential to initiate myogenic gene expression, they were not yet committed to 
complete the process and form muscle cells. The transplantation of the human ES-derived 
precursors to NOD-SCID mice injured with cardiotoxin and irradiation resulted in the 
incorporation of approximately 28% of cells into host myofibers. In the adult environment, 
hES cells derived precursors followed the same sequence of muscle development as during 
embryogenesis: myoblasts expressed muscle-specific structural proteins, fused together to 
form myotubes and to mature into myofibers. Hybrid regenerated myofibers displayed 
striated myofibrils and expressed desmin, actinin, troponin I, dystrophin (human) and 
myosin heavy chain. The transplanted hES cells also gave rise to satellite cells, which can 
provide a semi-permanent source of donor cells (Zheng et al., 2006). 
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A mouse ES cell line (ZHTc6-MyoD) was established by Ozasa et al. (2007) by introducing a 
Myod1 transgene controlled by a Tet-Off system. This cell line is feeder-free, proliferates 
indefinitely and has the potential to differentiate almost exclusively into the myogenic lineage 
in the absence of doxycycline, and without pre-differentiation into embryoid bodies. To start 
the differentiation process, doxycycline is removed and a differentiation medium containing 
4% fetal bovine serum (FBS) is used. Although other FBS concentrations were tested, the best 
one for differentiation was found to be 4%. The morphology of ZHTc6-MyoD cells in an 
undifferentiated state is round, but after changing to differentiation medium, they became 
elongated. After seven days, they started to fuse into myotubes, and occasional light muscle 
contractions were observed. Besides Myod1 expression, the expression of desmin (day 4), 
myogenin (day 4) and dystrophin (day 8) was detected by Western blotting.  Pax7, Myod1, 
desmin, myosin heavy chain and dystrophin expression was assayed by immuno-
histochemical analysis. The cell’s potential to differentiate into myofibers in vivo was also 
investigated by intramuscular injections into mdx mice and clusters of dystrophin-positive 
myofibers were detected in the injected area (Ozasa et al., 2007). 
The use of hES cells in regenerative medicine requires pure cell populations, so that specific 
precursors are isolated; this is important to control cell differentiation into the desired 
lineage and avoid problems, such as teratomas. Barberi et al. (2007) developed a feeder-free 
induction system in monolayer culture to derive mesenchymal precursors from hES cells.  
The isolation of mesenchymal precursors was made using FACS (fluorescent activated cell 
sorting) of CD73+ cells, from which skeletal myoblasts were isolated by selecting for the 
expression of Ncam1 (neural cell adhesion molecule 1) in another round of cell sorting. 
When induced with N2 medium, these skeletal myoblasts underwent terminal 
differentiation and formed contractile myotubes. The majority of Ncam1+ cells expressed 
Myod1 and Myog in both undifferentiated and differentiated condition; however, the 
expression of mature muscle protein markers, such as myosin heavy chain 2a, desmin, 
skeletal muscle actin and sarcomeric myosin were present only in cells in terminal 
differentiation. After transplantation into a muscle injury model, long-term engraftment of 
hES cell-derived skeletal myoblasts was observed (Barberi et al., 2007). 
One of the reasons for the difficulty in obtaining skeletal muscle progenitors from ES cells is 
the scarcity of paraxial mesoderm formation in the embryoid body, due to the lack of signals 
from the neural tube and notochord that are only present in the embryo. Enhancement of 
paraxial mesoderm formation was  achieved by Darabi et al. (2008) by inducing Pax3 by 
doxycyclin and sorting EBs for the presence of the PDGF-┙ receptor (Pdgfr1) a paraxial 
mesoderm marker, and absence of Flk1 (synonymous with VEGFR in humans), which is a 
lateral plate mesoderm marker. The PDGF┙R+Flk1- (Pdgfr1+/Flk1-) cell population is 
enriched under Pax3 induction for doxycycline, once paraxial mesoderm expansion is Pax3 
dependent in the embryo; this population shows proliferative capacity and myogenic 
potential. However, terminal muscle differentiation occurs only when Pax3 expression is 
removed and the cells exposed to a differentiation medium containing 2% horse serum. 
When transplanted into the tibialis anterior muscle of Rag2-/-γc-/- mice injured with 
cardiotoxin, the Pdgfr1+/Flk1- cells do not form teratomas and show muscle regeneration 
without the necessity of continuous Pax3 induction. In mdx mice, these cells exhibited 
significant engraftment and better functional properties (Darabi et al., 2008). 
The majority of transplantation experiments have been carried out in recessive models of 
muscular dystrophy, so it is unknown whether the same cellular therapies would produce 
equivalent results in dominant models. To address this question, Darabi et al. (2009) tested 
the therapeutic potential of the Pax3 induced Pdgfr1+/Flk1- cells in Frg1 transgenic mice, a 
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model for the dominant facioscapulohumeral muscular dystrophy (FSHD). Consistent with 
the results of the previous work, these cells showed appropriate engraftment and brought 
amelioration to muscle contractile properties, especially in males, perhaps due to gender 
differences. This work confirms the therapeutic potential of stem cells to treat both recessive 
and dominant forms of muscular dystrophy. 
According to Sakurai et al. (2008) the Pdgfr1+ population, when either positive or negative for 
Flk1, clearly consisted of paraxial mesoderm precursors, confirmed by the expression  Msgn1 
(mesogenin), Mesp2 and Tbx6. However, myotome and myogenic markers are not expressed 
by Pdgfr1+ cells, indicating that these cells have progressed to an early somatic stage, but are 
not yet completely committed to a specific lineage. When transplanted into the injured 
quadriceps femoris muscle of KSN nude mice, the Pdgfr1+ mesodermal progenitors are 
localized in the interstitial zone of muscles, adjacent to the myofibers. This localization 
suggests that these progenitor cells differentiated into satellite cells, which is confirmed by the 
expression of Pax7 and Cd34. Some progenitor nuclei are found in the center of myofibers, 
indicating the contribution of Pdgfr1+ cells to muscle regeneration (Sakurai et al., 2008). 
The culture of EBs in a differentiation medium composed by DMEM, 0.1 mM nonessential 
amino acids, 0.1 mM 2-mercaptoethanol, 5% horse serum and 10% fetal bovine serum, gives 
rise to cells expressing Pax7, but not Myod1, indicating the presence of quiescent satellite 
cells (Chang et al., 2009). These Pax7 positive cells were enriched by fluorescense activated 
sorting using the surface marker SM/C-2.6 antibody, typical of quiescent adult and neonatal 
mouse satellite cells. The SM/C-2.6 positive cells represented 15.7% of the EB derived cells. 
The SM/C-2.6 positive population showed myogenic potential both in vitro and in vivo 
experiments. In vivo, GFP+SM/C-2.6-positive cells were injected directly into cardiotoxin 
damaged muscles of mdx mice and were localized between the basal lamina and the muscle 
cell plasma membrane, which is the same location as satellite cells. After a second injury, a 
contribution of the injected cells to regeneration was observed, evidenced by the presence of 
GFP positive muscle fibers with central nuclei. In addition, the GFP+SM/C-2.6-positive cells 
were able to proliferate, and to replace recipient satellite cells that were still present 24 
weeks after transplantation, which is important for a continuous regeneration of the 
surrounding tissue (Chang et al., 2009). 
A summary of all published experiments to date are in table 1. 
 
 
Table 1. Summary of experiments testing the myogenic potential of ES cells. 
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5. Conclusion 
Several attempts to achieve appropriate differentiation of ES cells and implantation into 
model organisms have been tested with mixed results. The differentiation into the muscular 
lineage could be successfully obtained in vitro, as evidenced by the expression of myogenic 
markers.  However, despite attempts to direct in vivo differentiation, to date few reports 
have documented successful long term therapeutic results using these procedures. 
Strategies, such as selecting subpopulations of undifferentiated or partially differentiated 
embryonic stem cells before any kind of implantation treatment is undertaken, are emerging 
and should result in more homogenous cell populations and, diminish the frequency of 
maturation of stem cells into undesired cell types. In fact, the combination of several 
approaches, including cell sorting, genetic modification, and prior in vitro induction will 
probably be necessary to obtain successful therapeutic outcomes with ES cells. 
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